← Back to Search

Anti-fungal

CAMB (Encochleated Amphotericin B) for Chronic Mucocutaneous Candidiasis (CAMB Trial)

Phase 2
Waitlist Available
Led By Alexandra Freeman, MD
Research Sponsored by Matinas BioPharma Nanotechnologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6-months
Awards & highlights

CAMB Trial Summary

This study is evaluating whether a new drug called cochleate amphotericin B can be used to treat mucocutaneous candidiasis infections.

Eligible Conditions
  • Chronic Mucocutaneous Candidiasis

CAMB Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6-months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Symptoms of mucocutaneous candidiasis
Secondary outcome measures
Adverse events, changes in laboratory parameters
Area under the plasma concentration versus time curve (AUC)
Peak Plasma Concentration (Cmax)
Other outcome measures
Long-term adverse events, changes in laboratory parameters
Candidiasis, Chronic Mucocutaneous

Side effects data

From 2008 Phase 2 trial • 143 Patients • NCT00145249
80%
Hypokalaemia
63%
Hypomagnesaemia
49%
Anaemia
33%
Vomiting
33%
Nausea
29%
Headache
22%
Insomnia
18%
Constipation
16%
Phlebitis
14%
Anorexia
12%
Thrombophlebitis
12%
Pyrexia
12%
Hyponatraemia
12%
Diarrhoea
12%
Sepsis
12%
Sinusitis
10%
Rash
10%
Herpes simplex
10%
Bacteraemia
8%
Oral candidiasis
8%
Upper respiratory tract infection
8%
Thrombocytopenia
6%
Depression
6%
Asthenia
6%
Neutropenia
6%
Papilloedema
6%
Rash papular
6%
Dehydration
6%
Pruritus
6%
Hyperkalaemia
4%
Intracranial pressure increased
4%
Cough
4%
Convulsion
4%
Hypotension
4%
Blood creatinine increased
4%
Hypertension
4%
Chills
4%
Respiratory failure
2%
Hepatitis
2%
Cardio-respiratory arrest
2%
Escherichia sepsis
2%
AIDS related complication
2%
Central nervous system lymphoma
2%
Pain in extremity
2%
CSF pressure increased
2%
Subdural haematoma
2%
Toxoplasmosis
2%
Cardiac failure congestive
2%
Cerebral haemorrhage
2%
Congestive cardiomyopathy
2%
Prothrombin time prolonged
2%
Psychotic disorder
2%
Pneumocystis jiroveci pneumonia
2%
Immune reconstitution syndrome
2%
Meningitis cryptococcal
2%
Pseudomonal bacteraemia
2%
Back pain
2%
Pneumonia
2%
Herpes zoster
2%
Cerebral infarction
2%
Cachexia
2%
Cholangitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
AmphoB + Fluc800
AmphoB Standard
AmphoB+Fluc400

CAMB Trial Design

1Treatment groups
Experimental Treatment
Group I: CAMB (Encochleated Amphotericin B)Experimental Treatment1 Intervention
Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amphotericin B
2010
Completed Phase 2
~1000

Find a Location

Who is running the clinical trial?

Matinas BioPharma Nanotechnologies, Inc.Lead Sponsor
7 Previous Clinical Trials
685 Total Patients Enrolled
Alexandra Freeman, MDPrincipal InvestigatorNational Institute of Allergy and Infectious Diseases (NIAID)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Massachusetts
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
2016. "CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02629419.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top